Abstract | AIMS: METHODS: A retrospective chart review was conducted on 31 patients with a diagnosis of pigmentary retinal dystrophy prescribed VPA at a single centre. Visual field (VF), visual acuity (VA), length of treatment, liver enzymes and side effects were analysed. VF areas were defined using Goldmann VF (GVF) tracings recorded before, during and after VPA treatment using the V4e isopter for each eye. Using custom software, planimetric areas of VF were calculated. RESULTS: Five of the patients (10 eyes) had two Goldmann VF tracings, allowing comparison between baseline and follow-up VF. After 9.8 months of VPA, VF decreased by 0.145 cm(2) (26.478%) (p=0.432). For 22 of the patients (41 eyes), VA data was available, and logarithm of the minimum angle of resolution (logMAR) score changed by 0.056 log units (representing a decline in VA) after 14.9 months on VPA (p=0.002). Twelve patients (38.7%) reported negative side effects related to VPA use. CONCLUSIONS: VPA plays a complex role in patients with pigmentary retinal dystrophies and may be associated with VA and field decline as well as adverse side effects. Physicians should use caution with using VPA for pigmentary retinal dystrophies.
|
Authors | Sheena Bhalla, Deval Joshi, Shaminder Bhullar, Daniel Kasuga, Yeonhee Park, Christine N Kay |
Journal | The British journal of ophthalmology
(Br J Ophthalmol)
Vol. 97
Issue 7
Pg. 895-9
(Jul 2013)
ISSN: 1468-2079 [Electronic] England |
PMID | 23603755
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- GABA Agents
- Valproic Acid
|
Topics |
- Adolescent
- Adult
- Follow-Up Studies
- GABA Agents
(adverse effects, therapeutic use)
- Humans
- Liver Function Tests
- Middle Aged
- Retina
(physiopathology)
- Retinitis Pigmentosa
(drug therapy, physiopathology)
- Retrospective Studies
- Treatment Outcome
- Valproic Acid
(adverse effects, therapeutic use)
- Visual Acuity
(physiology)
- Visual Field Tests
- Visual Fields
(physiology)
- Young Adult
|